New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
05:55 EDTDNA, DNA, DNA, DNA, MNKD, MNKD, MNKD, MNKD, BMY, BMY, BMY, BMY, ARDM, ARDM, ARDM, ARDM, HGSI, HGSI, HGSI, HGSI, WST, WST, WST, WST, MEDI, MEDI, MEDI, MEDICambridge Healthtech Institute to host a conference
12th Annual Pep Talk: Protein Science Week is being held in Palm Springs, California on January 21-25.
News For DNA;MNKD;BMY;ARDM;HGSI;WST;MEDI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 20, 2015
07:21 EDTBMYUBS to hold a conference
Subscribe for More Information
May 19, 2015
16:01 EDTMNKDOptions Update; May 19, 2015
iPath S&P 500 VIX Short-Term Futures down 27c to 19.17. Option volume leaders: AAPL BAC WMT MSFT FB TWTR MNKD NFLX T PBR
08:57 EDTBMYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:56 EDTBMYGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:45 EDTBMYJacobs Engineering receives contract from Bristol-Myers
Jacobs Engineering (JEC) received a contract from Bristol-Myers Squibb Company (BMY) to provide construction management services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. Jacobs is also providing architectural and engineering services for the facility, which is being built to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
May 18, 2015
05:50 EDTMNKDStocks with implied volatility movement; BBRY MNKD
Stocks with implied volatility movement; BlackBerry (BBRY) 55, MannKind (MNKD) 75 according to iVolatility.
May 15, 2015
08:23 EDTMNKDJefferies sees 'good interest' in MannKind's Afrezza
Subscribe for More Information
May 14, 2015
11:03 EDTBMYBristol-Myers treatment of progressive supranuclear palsy granted orphan status
Subscribe for More Information
10:41 EDTBMYAnalysts upbeat on Amgen's Kyprolis after ASCO abstracts
Subscribe for More Information
09:22 EDTBMYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:09 EDTBMYBristol-Myers down 1.3% after release of ASCO abstracts
Subscribe for More Information
May 13, 2015
13:12 EDTBMYSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
May 12, 2015
08:34 EDTWSTWest Pharmaceutical to develop two new R&D Centers
West Pharmaceutical Services announced a multi-year investment as part of the Company's evolving research and development strategy. West will add capabilities to all of its global Packaging Systems R&D facilities, and develop two new R&D Centers of Excellence, one in the Asia Pacific region and one in Europe, to leverage regional capabilities and expertise in parenteral drug packaging. In addition, a significant investment is being made in North America to expand the current R&D center located within the Exton, Pa. headquarters, and to upgrade the St. Petersburg, Fla. facility.
07:10 EDTARDMAradigm, OSU scientists to present results from PNTM study
Scientists from the Oregon State University, Corvallis and Aradigm Corporation demonstrated that Aradigm’s investigational drugs Lipoquin and Pulmaquin significantly reduced the growth of the pulmonary non-tuberculous mycobacteria infection after 3 weeks of once daily respiratory tract dosing in mice. The number of colony forming units of Mycobacterium Avium Subsp Hominissuis was reduced by 79% and 77% by Lipoquin and Pulmaquin, respectively compared to saline controls. In contrast, unencapsulated ciprofloxacin had no effect. The detailed description of this research and its findings will be presented at Session D108 entitled “Diagnosis and Management of Nontuberculous Mycobacteria Infections” at 1:30 pm-3:30 pm on Wednesday, May 20 at the American Thoracic Society 2015 International Conference in Denver, CO. The research reported in this publication was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R43AI106188. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
05:58 EDTMNKDStocks with implied volatility movement; MNKD BBRY
Subscribe for More Information
May 11, 2015
12:51 EDTMNKDOn The Fly: Top stock stories at midday
Subscribe for More Information
09:59 EDTMNKDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:21 EDTMNKDOn The Fly: Pre-market Movers
Subscribe for More Information
07:09 EDTARDMAradigm reports Q1 EPS (8c), one estimate (6c)
Reports Q1 revenue $8.77, one estimate $6.8M. As of March 31, cash and cash equivalents totaled $48.6M.
06:43 EDTMNKDMannKind downgraded to Underweight from Neutral at JPMorgan
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use